Global Ingredient Risk Index Botanical

Bifidobacterium Bifidum

Bifidobacterium bifidum

Also known as: B. bifidum, Bifidobacterium bifidum

26 მარ 2026

LOW RISK 2.0/10 How?

This ingredient is classified as unclassified risk (GIRI score: 2.0/10).

Known Safety Concerns

Same immunocompromised patient safety warnings as other probiotics
Viability at expiry varies significantly between products
Clinical evidence for specific health claims is variable
GI gas and bloating are common initial side effects

Contraindications

Same immunocompromised patient safety warnings as other probiotics
Viability at expiry varies significantly between products

═══════════════════════════════════════════════════════════════════════ -->

Information not yet available for this ingredient profile.

Bifidobacterium bifidum is a key probiotic species of the infant and adult gut microbiome. Used in supplements for digestive health, immune support, and IBS. Well tolerated in healthy adults. Same immunocompromised patient cautions apply as with all probiotics. The clinical evidence base for most specific health claims is modest.

Scientific Name: Bifidobacterium bifidum

Information not yet available for this ingredient profile.

SETI Score 50/100

Risk Level High risk

Scientific Confidence Low

Evidence Strength Limited

Key Benefit Botanical

Key Safety Concern Same immunocompromised patient safety warnings as other probiotics

Evidence Reviewed 10 PubMed studies

Scientific Confidence Low

Based on study quality, consistency, and recency

Executive Summary — Ingredient Assessment

SETI Score 50/100

Risk Level High risk

Evidence Strength Limited

Main Benefit Botanical

Main Safety Concern Same immunocompromised patient safety warnings as other probiotics

Ingredient Bifidobacterium Bifidum

Scientific name Bifidobacterium bifidum

Scientific Evidence Overview

10 studies reviewed
0 high-quality studies (meta-analysis or RCT)
Main clinical benefit observed: Botanical
Evidence consistency: High consistency across studies (100%)

Safety Signals

Same immunocompromised patient safety warnings as other probiotics
Viability at expiry varies significantly between products
Clinical evidence for specific health claims is variable
GI gas and bloating are common initial side effects

Evidence Strength Limited

Final Scientific Assessment

The available scientific evidence for Bifidobacterium Bifidum indicates notable safety signals that warrant caution. Use should be considered carefully and monitored, particularly in sensitive populations or alongside other medications.

Ingredient Bifidobacterium Bifidum

Evidence reviewed 10 peer-reviewed studies (last 10 years)

Scientific name Bifidobacterium bifidum

50 /100

Total SETI Score

High risk

Evidence quality	10/40
Evidence consistency	20/20
Safety signals	0/20
Study recency	10/10
Evidence transparency	10/10

Evidence Summary

10 studies reviewed
0 high-quality studies (meta-analysis or systematic review)
0 studies identified benefits or no safety concern (GREEN)
10 studies reported limited or advisory safety evidence (YELLOW)

Evidence Policy

Only peer-reviewed scientific literature indexed in PubMed or comparable databases is included in this evaluation. Commercial websites, blogs, and marketing materials are excluded. All references include direct traceable links to source documents.

Last updated: 24 მარ 2026, 09:12

Evidence Distribution

10 Other / unclassified

Observational / other LOW evidence YELLOW
Human Milk Oligosaccharide Synbiotic Alleviates Food Allergy in Mice by Modulating Gut Microbiota and Increasing Indole-3-lactic Acid Levels. ↗

PMID 41859771 ↗

Journal J Agric Food Chem

Year 2026

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41859771/

Chang S et al.. Human Milk Oligosaccharide Synbiotic Alleviates Food Allergy in Mice by Modulating Gut Microbiota and Increasing Indole-3-lactic Acid Levels.. J Agric Food Chem. 2026. PMID:41859771.
Observational / other LOW evidence YELLOW
Impact of 1,2-u03b1-L-fucosidase on pig enteric methane production and growth performance. ↗

PMID 41857672 ↗

Journal Anim Microbiome

Year 2026

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41857672/

Georgaki D et al.. Impact of 1,2-u03b1-L-fucosidase on pig enteric methane production and growth performance.. Anim Microbiome. 2026. PMID:41857672.
Observational / other LOW evidence YELLOW
Synbiotics regulate gut microbiota-derived indole-3-acetic acid production to modulate the intestinal barrier and improve antibiotic-associated diarrhea. ↗

PMID 41850377 ↗

Journal J Dairy Sci

Year 2026

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41850377/

Shan Y et al.. Synbiotics regulate gut microbiota-derived indole-3-acetic acid production to modulate the intestinal barrier and improve antibiotic-associated diarrhea.. J Dairy Sci. 2026. PMID:41850377.
Observational / other LOW evidence YELLOW
Bifidobacterium bifidum G9-1 and Quality of Life in Chronic Constipation: A Multicenter, Double-blind, Randomized Controlled Trial. ↗

PMID 41843723 ↗

Journal Digestion

Year 2026

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41843723/

Misawa N et al.. Bifidobacterium bifidum G9-1 and Quality of Life in Chronic Constipation: A Multicenter, Double-blind, Randomized Controlled Trial.. Digestion. 2026. PMID:41843723.
Observational / other LOW evidence YELLOW
The effect of short-term consumption of Bifidobacterium bifidum on the gut microbiome of obese individuals. ↗

PMID 41809656 ↗

Journal Exp Biol Med (Maywood)

Year 2026

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41809656/

Burakova I et al.. The effect of short-term consumption of Bifidobacterium bifidum on the gut microbiome of obese individuals.. Exp Biol Med (Maywood). 2026. PMID:41809656.
Observational / other LOW evidence YELLOW
ILA-producing bifidobacterium bifidum ameliorates chronic kidney disease via AHR signaling by modulating the gut-kidney axis. ↗

PMID 41794500 ↗

Journal Food Res Int

Year 2026

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41794500/

Hua Q et al.. ILA-producing bifidobacterium bifidum ameliorates chronic kidney disease via AHR signaling by modulating the gut-kidney axis.. Food Res Int. 2026. PMID:41794500.
Observational / other LOW evidence YELLOW
Bioactive metabolite profiling in mixed-species probiotic yogurt. ↗

PMID 41780866 ↗

Journal J Dairy Sci

Year 2026

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41780866/

Marole TA et al.. Bioactive metabolite profiling in mixed-species probiotic yogurt.. J Dairy Sci. 2026. PMID:41780866.
Observational / other LOW evidence YELLOW
Phytochemical Profiling and Characterization of Honeydew, Cantaloupe, and Galia Melon Peel Extracts for Potential Prebiotic Activities. ↗

PMID 41767835 ↗

Journal Food Sci Nutr

Year 2026

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41767835/

Sameed N et al.. Phytochemical Profiling and Characterization of Honeydew, Cantaloupe, and Galia Melon Peel Extracts for Potential Prebiotic Activities.. Food Sci Nutr. 2026. PMID:41767835.
Observational / other LOW evidence YELLOW
Advocating gut-retina connection and microbiota mediated pathways in management of age-related macular degeneration: Preclinical to clinical perspective. ↗

PMID 41759744 ↗

Journal Ageing Res Rev

Year 2026

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41759744/

Waghmare PV et al.. Advocating gut-retina connection and microbiota mediated pathways in management of age-related macular degeneration: Preclinical to clinical perspective.. Ageing Res Rev. 2026. PMID:41759744.
Observational / other LOW evidence YELLOW
Exploring the frontier of oral nanomedicine in colorectal cancer therapy: Folate-targeted 5FU-Nisin-Selenium conjugates and probiotic-rich diets as a novel approach. ↗

PMID 41809887 ↗

Journal Asian J Pharm Sci

Year 2025

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41809887/

Derakhshan-Sefidi M et al.. Exploring the frontier of oral nanomedicine in colorectal cancer therapy: Folate-targeted 5FU-Nisin-Selenium conjugates and probiotic-rich diets as a novel approach.. Asian J Pharm Sci. 2025. PMID:41809887.

Q × L × D × S × 10 = 2.0 / 10

The GIRI Score is the product of four independently computed evidence components, each normalised to 0–1, then scaled to 0–10. Every component is derived exclusively from peer-reviewed references and regulatory data — no editorial judgement is applied.

0 of 10 approved references (score saturates at 10). More peer-reviewed studies = stronger evidence base.

Method: Q = number of approved references ÷ 10 (capped at 1.0)

50%

Limited — mostly case reports or animal studies

Method: L = mean study-level weight across approved references. Level 1 (meta-analysis / systematic review) = 1.0; Level 2 (RCT) = 0.8; Level 3 (cohort/case-control) = 0.6; Level 4 (case report) = 0.4; Level 5 (animal / in-vitro) = 0.2.

Benefit

Risk

50%

Mixed or neutral — roughly equal benefit and risk signals

Method: D = (sum of risk-scored references − sum of benefit-scored references) ÷ total evidence score, then scaled from [−1, 1] to [0, 1]. 0.0 = pure benefit; 0.5 = neutral; 1.0 = pure risk.

50%

One or more monitoring-level safety signals active

Method: S = 0.5 (neutral baseline) + sum of active signal severity deltas ÷ 10. Severity deltas: Critical = +2.0, High = +1.5, Moderate = +1.0, Low = +0.5. Capped at 1.0.

0Q × 5L × 5D × 5S = 2.0 / 10

Final GIRI Score for Bifidobacterium Bifidum. Risk level thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.

Full methodology & data sources

The GIRI Score is computed entirely from structured data — no editorial scoring or subjective weighting is applied at any step.

References: Only approved references are counted. Each reference is assigned an evidence level (L1–L5) and a direction (risk / neutral / benefit) by the reference manager or AI classifier.
Safety Signals: Sourced from regulatory agencies (FDA, EMA, Health Canada, TGA, and others) and pharmacovigilance databases. Only active signals count toward the score.
Formula version: GIRI Score v3.7.0 — Q × L × D × S × 10.
Limitations: The score reflects published evidence and recorded signals as of the last update date. It is not a clinical risk assessment and should not replace advice from a qualified healthcare professional.

LOW RISK 2.0/10

Based on available regulatory signals and scientific evidence, this ingredient presents a low safety concern under normal conditions of use.

LOW
0–3.0

MODERATE
3.0–5.5

HIGH
5.5–7.5

CRITICAL
7.5–10

2.0

The score pin shows exactly where this ingredient falls on the fixed risk scale.

What drove the Low classification for Bifidobacterium Bifidum

A score of 2.0 places this ingredient in the Low band. Thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.

0 approved references.

Limited — mostly case reports or animal studies (Level 4–5).

Neutral or mixed — benefit and risk signals roughly balanced.

No active signals — S component is at neutral baseline (0.5), contributing no extra risk weight.

No major regulatory restrictions or advisories recorded across monitored jurisdictions (FDA, EMA, Health Canada, TGA, and others).

How are the Low / Moderate / High / Critical thresholds defined?

The four risk levels are fixed score bands. A score is assigned to exactly one level based on where it falls:

Level	Score	Meaning
LOW	0.0 – 2.9	Sparse or predominantly beneficial evidence. No active safety alerts.
MODERATE	3.0 – 5.4	Mixed signals — some risk alongside benefit. Caution at high doses or in sensitive groups.
HIGH	5.5 – 7.4	Multiple studies or regulatory alerts documenting adverse effects. Professional oversight recommended.
CRITICAL	7.5 – 10	Regulatory restrictions in one or more major jurisdictions. Serious documented harm. Avoid without specialist supervision.

Thresholds are fixed constants (GIRI_Score_Utils::LEVEL_THRESHOLDS). They do not change per ingredient and are never subject to editorial adjustment.

← Back to Ingredient Database

Bifidobacterium Bifidum

Safety Profile

Known Safety Concerns

Contraindications

Interactions

Evidence and Scientific Findings

Ingredient Overview

Biological and Chemical Classification

Mechanism of Action

Clinical Evidence of Effectiveness

Pharmacokinetics

Recommended Dosage

SETI — Scientific Evidence Transparency Index

Executive Summary — Ingredient Assessment

Evidence Summary

Evidence Policy

Evidence Distribution

Score Transparency

Risk Level Classification

What drove the Low classification for Bifidobacterium Bifidum

ბოლო სიახლეები

500მლ პლასტმასის წყლის ბოთლები: ფარული საზოგადოებრივი ჯანმრთელობის რისკები

სკოლამდელი განათლება – მნიშვნელობა და გამოწვევები

ბავშვის უფლებები სკოლაში

პოპულარული ამბები

საუკეთესო ფილმები კულინარიის მოყვარულებისთვის

როგორ იყენებენ ახალგაზრდები ხელოვნურ ინტელექტს – სტუდენტების ხმა

კატეგორიები

ჩვენ შესახებ

გამოგვყევი სოციალურ ქსელებში